Wuhan YZY Biopharma Co (HKSE:02496) Net Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Wuhan YZY Biopharma Co's Net Income for the six months ended in Jun. 2024 was HK$-84.40 Mil. Wuhan YZY Biopharma Co's Revenue for the six months ended in Jun. 2024 was HK$0.00 Mil. Therefore, Wuhan YZY Biopharma Co's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Net Margin % or its related term are showing as below:

HKSE:02496's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

Wuhan YZY Biopharma Co Net Margin % Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Net Margin % Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

Net Margin %

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24
Net Margin %	-	-	-	-	-

Competitive Comparison of Wuhan YZY Biopharma Co's Net Margin %

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Net Margin % falls into.

Wuhan YZY Biopharma Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Wuhan YZY Biopharma Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-209.68	/	0
	=	%

Wuhan YZY Biopharma Co's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin	=	Net Income (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-84.397	/	0
	=	%

Wuhan YZY Biopharma Co (HKSE:02496) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Wuhan YZY Biopharma Co Net Margin % Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.

Executives

Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie	2201 Interest of corporation controlled by you
Wu Shangzhi	2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co Headlines

No Headlines